The 2026 ASCO Genitourinary Cancers Symposium was held at San Francisco's Moscone Center. (Photo: Mak Studio/iStock.com)
Physicians and scientists from Winship Cancer Institute of Emory University presented new research at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco, Feb. 26–28.
Centered around the theme, “Patient-Centered Care: From Discovery to Delivery,” the symposium aims to translate the latest research breakthroughs into improved clinical practices and patient outcomes.
Mehmet Asim Bilen, MD
Winship investigators shared insights from promising studies of prostate, renal cell, adrenal, penile, testicular and urethral cancers. Together, the studies reflect a growing emphasis on precision medicine and the use of advanced imaging, genomics and artificial intelligence to tailor the latest treatments to a patient’s unique disease biology and health profile.
“The research presented at this year’s ASCO GU Cancers Symposium underscores Winship’s leadership in advancing innovative, patient-centered approaches for people with genitourinary cancers,” says Mehmet Asim Bilen, MD, director of Winship’s Genitourinary Medical Oncology Program and professor of hematology and medical oncology at Emory University School of Medicine. “Our teams are dedicated to improving outcomes while enhancing the patient experience across every stage of the care continuum.”
Winship Presentations
- Hilmi Al-Shakhshir, MS
Characterizing frailty and its drivers in bladder cancer using machine learning-derived vulnerability and resource phenotypes. - Mehmet Asim Bilen, MD
Real-world comparison of prostate-specific antigen (PSA) response in metastatic castration-sensitive prostate cancer (mCSPC) patients treated with apalutamide (APA) without docetaxel vs darolutamide (DARO) without docetaxel.
Long-term efficacy and patient experience with neoadjuvant cabozantinib for locally advanced renal cell carcinoma. - Margo Gerke
Body composition metrics and clinical outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-617. - Ashesh B. Jani, MD
Association of a post-prostatectomy digital pathology-based multimodal artificial intelligence (MMAI) biomarker with nodal and extrapelvic metastasis on PET/CT at the time of biochemical recurrence and event-free survival following salvage radiotherapy.
Detection of bone metastases in men with low PSA biochemical recurrence of prostate cancer with 18F-flotufolastat PET/CT: A post-hoc analysis from the phase 3 SPOTLIGHT study.
Diagnostic performance of 18F-flotufolastat PET/CT compared with conventional imaging in men with biochemical recurrence of prostate cancer: Descriptive post-hoc analysis from the phase 3 SPOTLIGHT study.
Genomic risk classifier performance in PET-guided post-prostatectomy patients: Secondary analysis of a randomized trial. - Himanshu Maurya
Proliferation- and immune-informed fusion of multiscale image features for bladder cancer prognosis. - Ravi B. Parikh, MD, MPP
Machine learning-based phenotyping and trial emulation to identify checkpoint inhibitor responders in advanced urothelial cancer.